On 20 November, members of the EPAD WP6 communication team held a one day meeting in Amsterdam to update the communication plan for the final two years of the project. The team discussed the updated project’s communication strategy, focus plan and activities for 2018-2019. The participants started to review the communication activities undertaken from 2015-2017.…
On 3rd November, we presented the first analysis of the EPAD data at CTAD (Clinical Trials on Alzheimer’s Disease) in Boston, USA. This analysis was primarily illustrative as did not come from the first data wave officially to be released when we have full baseline data from our first 500 research participants (due early…
What is your current role in EPAD? I wear two hats within EPAD. Firstly I work for WP3, which is led by Pieter Jelle Visser at VUmc and Gerald Luscan at Pfizer. Together with a great team of colleagues, I’m involved in the process of informing new cohorts and getting them connected to the Registry.…
What is your current role in EPAD? I am a member of the Executive committee, the CDEx clinical Mitterrand and balancing committee. What did you do prior to joining EPAD? I have been working in neuroscience drug development for nearly 16 years, at Merck and at Janssen. Tell us a bit about…
On 18-19 October, IMI organised its Stakeholder Forum 2017 in Brussels under the theme ‘Open innovation’. On the first day of the event, IMI was looked through the lens of open innovation and the results that IMI is delivering were discussed. The day was focused on the IMI’s public-private partnership model, some IMI flagship projects…
On 16-18 October, the European Prevention of Alzheimer’s dementia (EPAD) project organised its first IMI-AD Platform Disease Modelling Workshop in Edinburgh, UK. The aim of the meeting was to bring together the modelling community within IMI funded projects to facilitate and encourage interactions between the overlapping communities. On the first day, the chair of the…
A great occasion to get to know more on three Alzheimer’s Disease IMI (Innovative Medicines Initiative) projects, was at the 27th Alzheimer Europe Conference (#27AEC), held in Berlin from 2-4 October. At a symposium convened by Eli Lilly, entitled: “Engaging with patient organisations within IMI consortia to inform quality, relevance and value in Alzheimer’s research…
In September 2017, two articles about the EPAD project appeared in the media. On 19 September, the Italian newspaper “la Repubblica” published an article entitled “L’Alzheimer si combatte giocando d’anticipo” including an interview and quotes from Prof. Giovanni Frisoni from the University of Geneva. He highlighted the EPAD project and described it as “il piu…
The EPAD family bids a fond farewell to Lennert Steukers. Lennert worked full time as project manager for Janssen on the IMI-EPAD project and provided the overall management to the project. In this role, he notably supported the coordinator, executive committee and the WP leaders in day-to-day management. He was also involved in EPAD’s internal…
The EPAD project reached the halfway of the project in June 2017. Given that all IMI projects are subject to an official Mid Term Review, EPAD held its IMI Mid-Term Review meeting on 15 September 2017 in Brussels, Belgium. The WP leads presented their work and the overall project progress to an independent expert panel.…
